Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNotes PayablesPayablesProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

China SXT Pharmaceuticals (SXTC) Non-Current Assets (2018 - 2025)

China SXT Pharmaceuticals has reported Non-Current Assets over the past 8 years, most recently at $310889.0 for Q3 2025.

  • For Q3 2025, Non-Current Assets fell 96.55% year-over-year to $310889.0; the TTM value through Sep 2025 reached $310889.0, down 96.55%, while the annual FY2025 figure was $367017.0, 95.87% down from the prior year.
  • Non-Current Assets for Q3 2025 was $310889.0 at China SXT Pharmaceuticals, down from $367017.0 in the prior quarter.
  • Over five years, Non-Current Assets peaked at $11.3 million in Q1 2021 and troughed at $310889.0 in Q3 2025.
  • A 5-year average of $7.3 million and a median of $9.4 million in 2022 define the central range for Non-Current Assets.
  • Biggest five-year swings in Non-Current Assets: surged 724.5% in 2024 and later plummeted 96.55% in 2025.
  • Year by year, Non-Current Assets stood at $11.0 million in 2021, then dropped by 10.79% to $9.8 million in 2022, then crashed by 88.87% to $1.1 million in 2023, then surged by 724.5% to $9.0 million in 2024, then plummeted by 96.55% to $310889.0 in 2025.
  • Business Quant data shows Non-Current Assets for SXTC at $310889.0 in Q3 2025, $367017.0 in Q1 2025, and $9.0 million in Q3 2024.